Fig. 1
Source: Himmerich & Treasure (2018) ‘Psychopharmacological advances in eating disorders’
Schematic showing pharmacotherapies that have been investigated in the treatment of the three core EDs (AN, BN and BED) and their conceptual modes of action. This includes the hedonic (cannabinoid, opioid and dopamine-related), self-regulatory (serotonin and glutamate-related), homeostatic (histamine, CART and neuropeptide Y related) and peripheral metabolic (leptin, ghrelin, insulin GLP-1) systems.